Delos Capital

SBU microRNA tech sparks $10M anticancer startup

By GREGORY ZELLER // A Stony Brook University-developed technology, a Massachusetts-based startup and an eight-figure investment from China could pave a path toward groundbreaking cancer therapeutics. Through an agreement with the Research Foundation of the State University of New York, a microRNA-manipulating technology developed by SBU biochemist Jingfang Ju has been licensed to Curamir Therapeutics, a startup launched in August on a $10 million stake from Hong Kong-based international innovation financer Delos Capital. Terms of…